Ikibazo gihuza ibibazo · Hagati Urwego
AI mu bigeragezo bya Clinical
Ongera usuzume uburyo AI ishyigikira guhuza abarwayi, igishushanyo mbonera, ubushakashatsi bujyanye n'imihindagurikire y'ikirere, kugenzura umutekano, no kwemeza amabwiriza mu bushakashatsi ku mavuriro.
Ikibazo 1 Bya 8
Ni ikihe kibazo kimaze igihe kinini mubigeragezo bivura AI yibanda cyane?
Reba buri kibazo8 ibibazo
Ibisubizo nibisobanuro bigaragara mugihe ufata ikibazo.
- Ni ikihe kibazo kimaze igihe kinini mubigeragezo bivura AI yibanda cyane?
- Buhoro kandi bigoye kwinjiza abarwayi
- Ibara ryimiti ipakira
- Ibitaro bya cafeteria
- Parikingi iboneka ahabigenewe
- How can natural-language processing help screen patients for clinical trials?
- Mugusiba isubiramo ryumutekano
- Extract clinical information from electronic health records and compare it with trial eligibility criteria
- Mu kwishyura abarwayi kuruta abanywanyi
- Mugabanya urubanza kugeza kumunsi umwe
- What is an external control arm in a clinical trial?
- Igikoresho cya robo
- Molekile ikomoka kuri mudasobwa
- A comparison group drawn from data outside the trial, such as historical or concurrent external data
- Ububiko bwibitse bwa seriveri
- What can propensity-score matching do when constructing an external-control comparison?
- Gutondeka inyuguti
- Igisekuru gisanzwe cyonyine
- Kugenzura
- Balance measured baseline covariates related to treatment assignment
- Ni ukubera iki guhanura guta ishuri hamwe nibikorwa-byerekana imikorere bifite akamaro kubaterankunga?
- Baretse abaterankunga kugira icyo bakora mbere yo guhagarara
- Bashushanya inyubako
- Bandika amagambo yo kwamamaza
- Bahitamo imyenda y'abakozi
- What does FDA’s January 2025 draft AI guidance address for drugs and biologics?
- Kugabanya ubushakashatsi bwose burundu
- AI used to generate information supporting regulatory decisions about safety, effectiveness, or quality
- Kuberako AI itemewe mubuvuzi
- Kugabanya umubare wabaganga
- What can a Bayesian adaptive clinical-trial design change as evidence accumulates?
- The original trial question after results are known
- The identity of past participants
- Trial elements such as dosing or allocation to study arms under prespecified rules
- The inclusion criteria without documentation
- Which pharmacovigilance tasks does FDA identify as possible uses for emerging AI?
- Only advertising click-through rates
- Satellite images of clinical sites
- Unrelated social-media sentiment about packaging
- Adverse-event intake, data entry, processing, and safety-signal detection or evaluation